About TRYNGOLZA

TRYNGOLZA is a GalNAc conjugated antisense oligonucleotide inhibitor of apolipoprotein C-III (apoC-III) production1

GalNAc enables targeted delivery to the liver, 
where apoC-III mRNA is generated1,12

ApoC-III is known to:

  • Inhibit lipoprotein lipase (LPL), the primary mechanism by which plasma triglycerides are hydrolyzed4
  • Regulate the metabolism of triglyceride-rich lipoproteins through LPL-independent pathways, which play an important role in patients with familial chylomicronemia syndrome (FCS) who have a substantial deficit of LPL activity4

GalNAc=triantennary N-acetylgalactosamine; mRNA=messenger ribonucleic acid.

TRYNGOLZA & apoC-III mRNA BindingTRYNGOLZA & apoC-III mRNA Binding

TRYNGOLZA is designed to work by1:

MOA Stage 1 Binding Carousel Image
MOA Stage 2 Degrading Carousel Image
MOA Stage 3 Reduction Carousel Image
 
 
MOA Stage 2 Degrading Carousel ImageMOA Stage 2 Degrading Carousel ImageMOA Stage 3 Reduction Carousel Image
Microscope Icon

By reducing apoC-III, TRYNGOLZA promotes metabolism and hepatic clearance of triglycerides through both LPL-independent and LPL-dependent pathways.1,4

Pharmacodynamics: sustained reductions observed in fasting apoC-III from baseline over 1 year1

ApoC-III is a regulator of triglyceride metabolism.4

Chart showing fasting apoc-III placebo-corrected mean percentage change from baseline after month 1, month 3, month 6 and month 12.Chart showing fasting apoc-III placebo-corrected mean percentage change from baseline after month 1, month 3, month 6 and month 12.

ChylomicronsChylomicrons
Chylomicrons